In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized

被引：60

作者：

Bebear, CM

Renaudin, H

Charron, A

Gruson, D

Lefrancois, M

Bebear, C

机构：

[1] Univ Bordeaux 2, Bacteriol Lab, F-33076 Bordeaux, France

[2] Lab Pfizer, F-91400 Orsay, France

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2000年 / 44卷 / 09期

关键词：

D O I：

10.1128/AAC.44.9.2557-2560.2000

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The in vitro activity of trovafloxacin against 125 strains of Mycoplasma species and Ureaplasma urealyticum, including fluoroquinolone-susceptible and fluoroquinolone-resistant species, was compared to those of other fluoroquinolones, doxycycline, and erythromycin. The MIC at which 90% of isolates are inhibited for all fluoroquinolone-susceptible strains was 0.25 mu g/ml. Whatever the associated mutations, trovafloxacin exhibited greater activity than the other fluoroquinolones tested against fluoroquinolone-resistant Mycoplasma hominis and U. urealyticum isolates.

引用

收藏

页码：2557 / 2560

页数：4

相关论文

共 10 条

[1]

[Anonymous], MOL DIAGNOSTIC PROCE

[2] Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis [J].

Bebear, CM ;

Renaudin, J ;

Charron, A ;

Renaudin, H ;

de Barbeyrac, B ;

Schaeverbeke, T ;

Bebear, C .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (04) :954-956

[3] Characterization of Mycoplasma hominis mutations involved in resistance to fluoroquinolones [J].

Bebear, CM ;

Bove, JM ;

Bebear, C ;

Renaudin, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) :269-273

[4] Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro [J].

Bébéar, CM ;

Renaudin, H ;

Charron, A ;

Bové, JM ;

Bébéar, C ;

Renaudin, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2304-2311

[5] In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas [J].

Bébéar, CM ;

Renaudin, H ;

Schaeverbeke, T ;

Leblanc, F ;

Bébéar, C .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (05) :711-714

[6] In vitro activity of BAY 12-8039, a new fluoroquinolone, against mycoplasmas [J].

Bébéar, CM ;

Renaudin, H ;

Boudjadja, A ;

Bébéar, C .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (03) :703-704

[7] In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates [J].

Felmingham, D ;

Robbins, MJ ;

Ingley, K ;

Mathias, I ;

Bhogal, H ;

Leakey, A ;

Ridgway, GL ;

Gruneberg, RN .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 :43-49

[8] Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance [J].

Hooper, DC .

CLINICAL INFECTIOUS DISEASES, 1998, 27 :S54-S63

[9] Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219) [J].

Kenny, GE ;

Cartwright, FD .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (04) :1048-1049

[10] IN-VITRO ACTIVITY OF THE NEW FLUOROQUINOLONE CP-99,219 [J].

NEU, HC ;

CHIN, NX .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (11) :2615-2622